FUJIKURA
23.10.2020 10:02:07 CEST | Business Wire | Press release
Fujikura Ltd. (TOKYO:5803) (President & CEO: Masahiko Ito) today announced the introduction of industry’s most advanced and highly integrated Phased Array Antenna Module (PAAM) for 5G mmWave operating in 3GPP bands n257 (28 GHz), n258 (26 GHz) and n261 (27 GHz). The Fujikura PAAM is the industry’s highest performance PAAM targeting indoor and outdoor applications such as 5G mmWave Fixed Wireless Access (FWA), 5G mmWave Mobile Wireless Access (MWA), 5G mmWave wireless backhaul, and other emerging applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201023005099/en/
Key Differentiating Features of the Fujikura PAAM
The Fujikura PAAM is a high performance phased array antenna module with a novel integrated antenna, and supports concurrent dual polarized beams in both transmission and reception (Fig.1). The PAAM integrates best-in-class mmWave-ICs developed in-house using an industry leading SiGe BiCMOS process. The PAAM features extremely low noise figure (NF) characteristics and enables a large link margin for expanded coverage. Tunable true-time-delay-type phase shifters support precise and independent phase and amplitude control over a wide frequency range. The unique phase shifter not only enables simple beam-steering control which allows accurate beam steering with fine resolution, but also allows calibration-free operation making PAAM installation much easier. The phase shifter also maintains the transmitted or received signals undistorted by providing invariant group delay and unchanged beam direction in a wide frequency range. In addition, Fujikura PAAM provides superior digital reconfigurability allowing (1) flexible choices in the trade-off space between NF and linearity --- this enables a wide range of coverage applications simply through digital reconfiguration of the PAAM, and (2) on-chip support for 1000s of beam configurations. These are exactly the features highly desired by 5G wireless equipment manufacturers.
5G mmWave Market Growth
Currently, 5G deployments are accelerating around the world and mmWave bands are expected to play a significant role in enhancing the network capabilities. According to the Global mobile Suppliers Association (GSA), by the end of August, 2020, 397 operators in 129 countries and territories had announced investments in 5G. The deployment of 5G mmWave has started primarily in the US market for FWA and MWA, and we are now in the early stages. Markets are expecting substantial increase in 5G mmWave use cases including both outdoor and indoor deployments around the world. Fujikura will contribute to this market growth and benefit from it by providing 5G mmWave infrastructure customers with best-in-class PAAM products.
“Fujikura is announcing its first 5G mmWave RF-IC products for mobile infrastructure. Fujikura n257/n258/n261 PAAM products leverage field proven 5G mmWave IC1 and antenna in package2 technologies developed at IBM Research and enhanced by a Fujikura-led Joint Development Program3,4 . Leveraging our expertise in antenna design and substrate technologies as well as our long history and expertise in delivering differentiating products to the telecom industry, we are excited to introduce our new PAAM product family,” said Kenji Nishide, Fujikura R&D Managing Executive Officer. “Fujikura’s PAAM sets new benchmarks in terms of performance and low power consumption with the highest level of integration for 5G mmWave RF-ICs, which will contribute to growth and expansion of 5G mmWave networks and services.”
Product Introduction Schedule
Fujikura will provide samples for early access customers by the end of 1Q 2021 with volume production in 2H 2021.
For More Information
Please visit our website (https://mmwavetech.fujikura.jp/#area-28ghz-module
) and contact us.
About Fujikura
Fujikura Ltd. is a Tokyo-based company that has been providing wires and cables—“Tsunagu,” or connecting, technologies— to build social infrastructure since its foundation in 1885. With this expertise cultivated over 130 years, we commit to contribute to building social infrastructure by developing products for optical fibers, broadband wireless transmission, superconducting wires, electric vehicles, and other advanced technologies. Fujikura Group has approximately 57,000 employees in more than 30 countries, and posted sales revenue of US$6,178.7 million in Fiscal 2019. Find out more at www.fujikura.co.jp/eng
.
Reference
[1] https://www.ibm.com/blogs/research/2018/02/isscc-lewis-winner-award/
[2] https://www.ibm.com/blogs/research/2017/06/using-air-cavity-boost-performance-5g-antenna-module/
[3] https://www.fujikura.co.jp/eng/newsrelease/products/2058964_11777.html
[4] https://mmwavetech.fujikura.jp/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease1.5.2026 23:28:00 CEST | Press release
Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi®(ruxolitinib)Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily JakafiJakafi XR will be available for pharmacy orders by May 8 Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meetin
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 18:08:00 CEST | Press release
Drivers and team members of Formula 1® were reunited with their loved ones during a night that also celebrated the new partnership between Barilla and the Visa Cash App Racing Bulls Formula 1® Team. A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines wer
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 12:07:00 CEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Andersen Consulting styrker sine kompetencer inden for digital transformation med Weexa1.5.2026 10:07:00 CEST | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Weexa, en global leverandør af løsninger inden for digital transformation, B2B-integration og digitalisering af forsyningskæden. Med hovedsæde i Frankrig leverer Weexa end-to-end-tjenester, der hjælper organisationer med at optimere, sikre og skalere deres digitale økosystemer. Virksomheden specialiserer sig i styring af B2B-datastrømme og digitalisering, hvilket muliggør problemfri kommunikation mellem applikationer både internt og på tværs af organisationer gennem teknologier som EDI, API'er og e-fakturering. Weexa tilbyder også SAP-integration og supply chain-løsninger til styring af lager og transport, sideløbende med strategisk rådgivning, projektlevering og vedligeholdelse af tredjepartsapplikationer. Weexa betjener organisationer inden for fødevaresektoren, detailhandel, engros, logistik, transport, bilindustrien, sundheds- og mediesektoren og hjælper globale virksomheder med at optimere deres ydeevne samt at overholde de nyeste
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 01:17:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom